Bioventus Inc. Stock Price, News & Analysis

Bioventus (Nasdaq: BVS) announced that CEO Ken Reali will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022, at 11:00 a.m. ET. A live webcast will be available on the Company’s website under the 'Investors' section, with a replay accessible after the event. Bioventus is recognized for delivering innovative, cost-effective solutions that promote healing and enhance patient quality of life. The Company focuses on pain treatment, restorative therapies, and surgical solutions.

Bioventus reported Q4 2021 net sales of $130.4 million, a 32.3% increase year-over-year, driven by recent acquisitions. However, the company faced a net loss of $1.9 million, compared to a net income of $2.3 million in the previous year. Full-year net sales reached $430.9 million, up 34.2% from 2020, alongside a decrease in net income to $9.6 million. For 2022, the company forecasts net sales between $545 million and $565 million, indicating strong growth prospects.

Bioventus Inc. (Nasdaq: BVS) has received 510(k) clearance from the US FDA for its upgraded StimRouter Neuromodulation System, designed to improve chronic pain management. This next-generation device offers enhanced patient control and longer battery life through the use of a smartphone app and a state-of-the-art external conductor. Thousands of patients have previously benefited from the StimRouter, which aims to support a non-opioid approach to pain relief, addressing the needs of over 50 million Americans suffering from chronic pain.

Bioventus (Nasdaq: BVS) announced the appointment of Mark Singleton as Senior Vice President and Chief Financial Officer, effective March 21, 2022. Singleton, who has over 20 years of experience in finance and operational roles, previously served at Teleflex, overseeing a $1.7 billion business. CEO Ken Reali stated that Singleton's experience and leadership qualities will enhance Bioventus' operational efficiencies and market leadership. Singleton expressed excitement about leveraging the company’s portfolio to drive growth and improve operating margins.

Bioventus (Nasdaq: BVS) announced it will report its financial results for Q4 and fiscal year 2021 on March 10, 2022, before the market opens. A conference call hosted by management will follow at 8:30 a.m. Eastern Time to discuss the results and provide a business update. The call can be accessed via phone or through a live webcast on the Investor Relations section of Bioventus' website. The webcast will be available for replay until March 9, 2023.

SWK Holdings Corporation (Nasdaq: SWKH) updated its portfolio performance for the second half of 2021, highlighting new financings including $10 million to MolecuLight and $12 million to Biotricity (NASDAQ: BTCY). CEO Winston Black noted that 2022 aims to restore deal origination to historical levels. Enteris BioPharma's partnership with Cara Therapeutics is advancing with a $5 million milestone payment. Additionally, Biolase (NASDAQ: BVS) anticipates a 44-47% revenue increase for the fourth quarter. SWK focuses on providing flexible financing solutions to small and mid-sized life science companies.

Bioventus (Nasdaq: BVS) announced preliminary revenue results for Q4 and full-year 2021, projecting revenues between $128.5 to $131.5 million for Q4, marking a 30% to 33% growth year-over-year, and $429 to $432 million for the full year, an increase of approximately 34%. CEO Ken Reali expressed pride in the team’s performance despite market challenges, highlighting strong growth in Pain Treatments and Bone Graft Substitutes. The company anticipates that recent acquisitions will meet or exceed expectations as it heads into 2022.

DURHAM, N.C., Dec. 28, 2021 – Bioventus (Nasdaq: BVS) announced that CEO Ken Reali will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 p.m. ET. The presentation will be accessible via a live webcast on the Bioventus investors website, and it will also be archived for later viewing. Bioventus is dedicated to providing innovative, clinically proven products that facilitate active healing and enhance patient recovery.

Bioventus (Nasdaq: BVS) has appointed Dr. Michelle McMurry-Heath to its Board of Directors, effective January 1, 2022. With over 20 years of experience in healthcare and regulatory roles, McMurry-Heath brings valuable insights to the company. Her previous positions include leading regulatory science at Johnson & Johnson and serving at the FDA. Bioventus aims to leverage her expertise in medical innovation and regulatory affairs to advance its offerings in pain treatment and restorative therapies. Company leadership expresses optimism about the strategic guidance she will provide.